Current Pharmacologic Approaches for Prevention and Treatment of Bronchopulmonary Dysplasia
暂无分享,去创建一个
[1] I. Liener,et al. Protection against pulmonary oxygen toxicity in rats by the intratracheal administration of liposome-encapsulated superoxide dismutase or catalase. , 2015, The American review of respiratory disease.
[2] L. Doyle,et al. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. , 2014, The Cochrane database of systematic reviews.
[3] A. Ohlsson,et al. Inositol for respiratory distress syndrome in preterm infants. , 2012, The Cochrane database of systematic reviews.
[4] R. Ehrenkranz,et al. Inhaled Nitric Oxide in Preterm Infants: An Individual-Patient Data Meta-analysis of Randomized Trials , 2011, Pediatrics.
[5] L. Brion,et al. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. , 2011, The Cochrane database of systematic reviews.
[6] L. Brion,et al. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. , 2011, The Cochrane database of systematic reviews.
[7] M. Walsh,et al. Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants. , 2011, American journal of respiratory and critical care medicine.
[8] Renee F Wilson,et al. Inhaled Nitric Oxide in Preterm Infants: A Systematic Review , 2011, Pediatrics.
[9] D. Rowitch,et al. NIH Consensus Development Conference Statement: Inhaled Nitric-Oxide Therapy for Premature Infants , 2011, Pediatrics.
[10] David J Henderson-Smart,et al. Methylxanthine treatment for apnoea in preterm infants. , 2010, The Cochrane database of systematic reviews.
[11] A. Greenough,et al. Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial , 2010, The Lancet.
[12] M. Matthay,et al. Mesenchymal stem cells for the prevention of bronchopulmonary dysplasia: delivering the secretome. , 2009, American journal of respiratory and critical care medicine.
[13] M. Laughon,et al. Prevention of bronchopulmonary dysplasia. , 2009, Seminars in fetal & neonatal medicine.
[14] O. Liang,et al. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. , 2009, American journal of respiratory and critical care medicine.
[15] S. Archer,et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. , 2009, American journal of respiratory and critical care medicine.
[16] W. Thomas,et al. Nonventilatory Strategies for Prevention and Treatment of Bronchopulmonary Dysplasia – What Is the Evidence? , 2008, Neonatology.
[17] E. Eichenwald,et al. Management and outcomes of very low birth weight. , 2008, The New England journal of medicine.
[18] D. Henderson-smart,et al. Methylxanthine treatment for apnea in preterm infants. , 2008, The Cochrane database of systematic reviews.
[19] L. Doyle,et al. Long-term effects of caffeine therapy for apnea of prematurity. , 2007, The New England journal of medicine.
[20] W. Poole,et al. Inhaled nitric oxide in infants >1500 g and <34 weeks gestation with severe respiratory failure , 2007, Journal of Perinatology.
[21] H. Christou,et al. Pharmacological strategies in the prevention and management of bronchopulmonary dysplasia. , 2006, Seminars in perinatology.
[22] G. Cutter,et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. , 2006, The New England journal of medicine.
[23] L. Brion,et al. Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. , 2006, The Cochrane database of systematic reviews.
[24] L. Doyle,et al. Caffeine therapy for apnea of prematurity. , 2006, The New England journal of medicine.
[25] M. Walsh,et al. Summary Proceedings From the Bronchopulmonary Dysplasia Group , 2006, Pediatrics.
[26] J. Carlin,et al. Low-Dose Dexamethasone Facilitates Extubation Among Chronically Ventilator-Dependent Infants: A Multicenter, International, Randomized, Controlled Trial , 2006, Pediatrics.
[27] R. Mitchell,et al. The role of stem cells in the response to myocardial and vascular wall injury. , 2005, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[28] C. Lachance,et al. Fluticasone Inhalation in Moderate Cases of Bronchopulmonary Dysplasia , 2005, Pediatrics.
[29] D. Phinney,et al. Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system. , 2005, Current pharmaceutical design.
[30] J. Crapo,et al. Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease. , 2005, American journal of physiology. Lung cellular and molecular physiology.
[31] B. Vohr,et al. Vitamin A Supplementation for Extremely Low Birth Weight Infants: Outcome at 18 to 22 Months , 2005, Pediatrics.
[32] K. Watterberg,et al. Prophylaxis of Early Adrenal Insufficiency to Prevent Bronchopulmonary Dysplasia: A Multicenter Trial , 2004, Pediatrics.
[33] V. Fellman,et al. N-Acetylcysteine Administration during the First Week of Life Does Not Improve Lung Function in Extremely Low Birth Weight Infants , 2004, Neonatology.
[34] C. Piantadosi,et al. Discordant extracellular superoxide dismutase expression and activity in neonatal hyperoxic lung. , 2004, American journal of respiratory and critical care medicine.
[35] A. Jobe,et al. Choice and dose of corticosteroid for antenatal treatments. , 2004, American journal of obstetrics and gynecology.
[36] K. Stenmark,et al. Predisposition of infants with chronic lung disease to respiratory syncytial virus-induced respiratory failure: a vascular hypothesis , 2004, The Pediatric infectious disease journal.
[37] V. Fellman,et al. N-acetylcysteine does not prevent bronchopulmonary dysplasia in immature infants: a randomized controlled trial. , 2003, The Journal of pediatrics.
[38] J. Marks,et al. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. , 2003, The New England journal of medicine.
[39] N. Laird,et al. Family-based association analysis of beta2-adrenergic receptor polymorphisms in the childhood asthma management program. , 2003, The Journal of allergy and clinical immunology.
[40] B. Lipworth,et al. Acute systemic effects of inhaled salbutamol in asthmatic subjects expressing common homozygous beta2-adrenoceptor haplotypes at positions 16 and 27. , 2003, British journal of clinical pharmacology.
[41] J. Davis,et al. Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. , 2003, Pediatrics.
[42] R. Ehrenkranz,et al. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. , 2003, The Cochrane database of systematic reviews.
[43] R. Ehrenkranz,et al. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. , 2003, The Cochrane database of systematic reviews.
[44] R. Ehrenkranz,et al. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. , 2003, The Cochrane database of systematic reviews.
[45] J. Cummings,et al. A Randomized Trial of Inhaled Versus Intravenous Steroids in Ventilator-Dependent Preterm Infants , 2002, Journal of Perinatology.
[46] M. Kennedy,et al. Beta-adrenergic receptor polymorphisms and drug responses in asthma. , 2002, Pharmacogenomics.
[47] P. Gressens,et al. Neurotoxic Effects of Fluorinated Glucocorticoid Preparations on the Developing Mouse Brain: Role of Preservatives , 2001, Pediatric Research.
[48] A. Jobe,et al. Prospects for research in reproductive health and birth outcomes. , 2001, JAMA.
[49] C. Patterson,et al. A multicenter, randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide. , 2001, Pediatrics.
[50] S. Wardle,et al. Randomised controlled trial of oral vitamin A supplementation in preterm infants to prevent chronic lung disease , 2001, Archives of disease in childhood. Fetal and neonatal edition.
[51] J. Fiascone,et al. Strategies for prevention of neonatal chronic lung disease. , 2000, Seminars in perinatology.
[52] F. Ducharme,et al. Inhaled steroids for neonatal chronic lung disease. , 1999, The Cochrane database of systematic reviews.
[53] J. Tyson,et al. VITAMIN A SUPPLEMENTATION FOR EXTREMELY-LOW-BIRTH-WEIGHT INFANTS , 1999 .
[54] J. Rychik,et al. Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia. , 1999, Pediatrics.
[55] A. Denjean,et al. Inhaled salbutamol and beclomethasone for preventing broncho-pulmonary dysplasia: a randomised double-blind study , 1998, European Journal of Pediatrics.
[56] E. Bancalari. Corticosteroids and neonatal chronic lung disease , 1998, European Journal of Pediatrics.
[57] N. Rifai,et al. Early High Dose Antioxidant Vitamins Do Not Prevent Bronchopulmonary Dysplasia in Premature Baboons Exposed to Prolonged Hyperosia: APilot Study , 1998, Pediatric Research.
[58] S. Ryan,et al. Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants , 1997, Archives of disease in childhood. Fetal and neonatal edition.
[59] Richard J Martin,et al. Effect of Exogenous and Endogenous Nitric Oxide on the Airway and Tissue Components of Lung Resistance in the Newborn Piglet , 1997, Pediatric Research.
[60] C. Poets,et al. Effects of salbutamol delivery from a metered dose inhaler versus jet nebulizer on dynamic lung mechanics in very preterm infants with chronic lung disease , 1997, Pediatric pulmonology.
[61] A. Meister,et al. L-2-oxothiazolidine-4-carboxylate, a cysteine precursor, stimulates growth and normalizes tissue glutathione concentrations in rats fed a sulfur amino acid-deficient diet. , 1995, The Journal of nutrition.
[62] D. Ivy,et al. Inhaled Nitric Oxide Improves Gas Exchange and Lowers Pulmonary Vascular Resistance in Severe Experimental Hyaline Membrane Disease , 1994, Pediatric Research.
[63] D. Durand,et al. Randomized trial of long-term diuretic therapy for infants with oxygen-dependent bronchopulmonary dysplasia. , 1994, The Journal of pediatrics.
[64] R. Wilkening,et al. Inhaled nitric oxide in the management of a premature newborn with severe respiratory distress and pulmonary hypertension. , 1993, Pediatrics.
[65] K. Kennedy. Epidemiology of acute and chronic lung injury. , 1993, Seminars in perinatology.
[66] C. Aebi,et al. Respiratory response to salbutamol (albuterol) in ventilator-dependent infants with chronic lung disease: pressurized aerosol delivery versus intravenous injection , 1993, Intensive Care Medicine.
[67] J. Davis,et al. Prophylactic effects of recombinant human superoxide dismutase in neonatal lung injury. , 1993, Journal of applied physiology.
[68] K. Watterberg,et al. Failure of cromolyn sodium to reduce the incidence of bronchopulmonary dysplasia: a pilot study. The Neonatal Cromolyn Study Group. , 1993, Pediatrics.
[69] K. Hoppu,et al. Inositol supplementation in premature infants with respiratory distress syndrome. , 1992, The New England journal of medicine.
[70] K. Barrington,et al. The Natural History of the Appearance of Apnea of Prematurity , 1991, Pediatric Research.
[71] A. Zipursky,et al. Failure of supplementation with vitamin E to prevent bronchopulmonary dysplasia in infants less than 1,500 g birth weight. , 1991, The European respiratory journal.
[72] B. Schmidt,et al. Respiratory response and pharmacokinetics of intravenous salbutamol in infants with bronchopulmonary dysplasia , 1990, Critical care medicine.
[73] R. Parker,et al. Double-blind, placebo-controlled trial of alternate-day furosemide therapy in infants with chronic bronchopulmonary dysplasia. , 1990, The Journal of pediatrics.
[74] A. Leviton,et al. Hydration during the first days of life and the risk of bronchopulmonary dysplasia in low birth weight infants. , 1990, The Journal of pediatrics.
[75] A. Rotschild,et al. Randomized, double-blind, controlled trial of long-term diuretic therapy for bronchopulmonary dysplasia. , 1989, The Journal of pediatrics.
[76] J. Brady,et al. Controlled trial of furosemide therapy in infants with chronic lung disease. , 1985, The Journal of pediatrics.
[77] P. Barnes,et al. Fetal pulmonary beta-adrenergic receptors: characterization in the human and in vitro modulation by glucocorticoids in the rabbit. , 1985, Pediatric pulmonology.
[78] A. Lazzara,et al. Pulmonary effects of furosemide in preterm infants with lung disease. , 1983, The Journal of pediatrics.
[79] A. Stark,et al. Bronchopulmonary dysplasia: possible relationship to pulmonary edema. , 1978, The Journal of pediatrics.
[80] Yahya Al Ethawi. Inhaled Nitric Oxide in Preterm Infants Undergoing Mechanical Ventilation , 2012, Journal of clinical neonatology.
[81] L. Doyle,et al. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. , 2009, The Cochrane database of systematic reviews.
[82] Richard J Martin. Long-Term Effects of Caffeine Therapy for Apnea of Prematurity , 2008 .
[83] B. Darlow,et al. Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants. , 2007, The Cochrane database of systematic reviews.
[84] H. Halliday,et al. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. , 2007, The Cochrane database of systematic reviews.
[85] R. Ehrenkranz. Caffeine Therapy for Apnea of Prematurity , 2007 .
[86] L. Monte,et al. [Bronchopulmonary dysplasia]. , 2005, Jornal de pediatria.
[87] H. Halliday,et al. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. , 2003, The Cochrane database of systematic reviews.
[88] L. Doyle,et al. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. , 2003, The Cochrane database of systematic reviews.
[89] S. Abbasi,et al. Pulmonary Function and Electrolyte Balance Following Spironolactone Treatment in Preterm Infants With Chronic Lung Disease: A Double-Blind, Placebo-Controlled, Randomized Trial , 2000, Journal of Perinatology.
[90] L. Brion,et al. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. , 2000, The Cochrane database of systematic reviews.
[91] D. Henderson-smart,et al. Methylxanthine treatment for apnea in preterm infants. , 2000, The Cochrane database of systematic reviews.
[92] J. Hasday,et al. Cromolyn sodium prophylaxis inhibits pulmonary proinflammatory cytokines in infants at high risk for bronchopulmonary dysplasia. , 1997, American journal of respiratory and critical care medicine.
[93] J. Davis,et al. Drug therapy for bronchopulmonary dysplasia , 1990, Pediatric pulmonology.
[94] J. Crapo,et al. Protection against oxygen toxicity by intravenous injection of liposome-entrapped catalase and superoxide dismutase. , 1984, The Journal of clinical investigation.